GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
Author(s) -
Simone Lanini,
Stefania Capone,
Andrea Antinori,
Stefano Milleri,
Emanuele Nicastri,
Roberto Camerini,
Chiara Agrati,
Concetta Castilletti,
Federica Mori,
Alessandra Sacchi,
Giulia Matusali,
Roberta Gagliardini,
Virginia Ammendola,
Eleonora Cimini,
Fabiana Grazioli,
Laura Scorzolini,
Federico Napolitano,
Maria Maddalena Plazzi,
Marco Soriani,
Aldo De Luca,
Simone Battella,
Andrea Sommella,
Alessandra M. Contino,
Federica Barra,
Michela Gentile,
Angelo Raggioli,
Yufang Shi,
Enrico Girardi,
Markus Maeurer,
Maria Rosaria Capobianchi,
Francesco Vaia,
Mauro Piacentini,
Guido Kroemer,
Alessandra Vitelli,
Stefano Colloca,
Antonella Folgori,
Giuseppe Ippolito
Publication year - 2021
Publication title -
science translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.819
H-Index - 216
eISSN - 1946-6242
pISSN - 1946-6234
DOI - 10.1126/scitranslmed.abj1996
Subject(s) - gorilla , covid-19 , virology , medicine , immunology , biology , outbreak , disease , infectious disease (medical specialty) , paleontology
GRAd-COV2, a candidate vaccine for COVID-19 based on a gorilla adenovirus, is safe and immunogenic in younger and older adults.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom